These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 15654225)

  • 21. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients.
    Fackenthal JD; Zhang J; Zhang B; Zheng Y; Hagos F; Burrill DR; Niu Q; Huo D; Sveen WE; Ogundiran T; Adebamowo C; Odetunde A; Falusi AG; Olopade OI
    Int J Cancer; 2012 Sep; 131(5):1114-23. PubMed ID: 22034289
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRCA1 and BRCA2 mutations in ethnic Lebanese Arab women with high hereditary risk breast cancer.
    El Saghir NS; Zgheib NK; Assi HA; Khoury KE; Bidet Y; Jaber SM; Charara RN; Farhat RA; Kreidieh FY; Decousus S; Romero P; Nemer GM; Salem Z; Shamseddine A; Tfayli A; Abbas J; Jamali F; Seoud M; Armstrong DK; Bignon YJ; Uhrhammer N
    Oncologist; 2015 Apr; 20(4):357-64. PubMed ID: 25777348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba.
    Rodriguez RC; Esperon AA; Ropero R; Rubio MC; Rodriguez R; Ortiz RM; Anta JJ; de los Rios M; Carnesolta D; del Olivera MC; Vansam SS; Royer R; Akbari MR; Donenberg T; Narod SA
    Fam Cancer; 2008; 7(3):275-9. PubMed ID: 18286383
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas.
    Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Francis W; Halliday D; Royer R; Zhang S; Li S; Thompson I; Donenberg T; Hurley J; Akbari MR; Narod SA
    Clin Genet; 2016 Mar; 89(3):328-31. PubMed ID: 25920394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian.
    Friedenson B
    MedGenMed; 2005 Jun; 7(2):60. PubMed ID: 16369438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
    Malone KE; Daling JR; Doody DR; Hsu L; Bernstein L; Coates RJ; Marchbanks PA; Simon MS; McDonald JA; Norman SA; Strom BL; Burkman RT; Ursin G; Deapen D; Weiss LK; Folger S; Madeoy JJ; Friedrichsen DM; Suter NM; Humphrey MC; Spirtas R; Ostrander EA
    Cancer Res; 2006 Aug; 66(16):8297-308. PubMed ID: 16912212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy.
    Golshan M; Miron A; Nixon AJ; Garber JE; Cash EP; Iglehart JD; Harris JR; Wong JS
    Am J Surg; 2006 Jul; 192(1):58-62. PubMed ID: 16769276
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The risk of breast cancer in BRCA1 and BRCA2 mutation carriers without a first-degree relative with breast cancer.
    Metcalfe KA; Lubinski J; Gronwald J; Huzarski T; McCuaig J; Lynch HT; Karlan B; Foulkes WD; Singer CF; Neuhausen SL; Senter L; Eisen A; Sun P; Narod SA;
    Clin Genet; 2018 May; 93(5):1063-1068. PubMed ID: 29206279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. After BRCA1 and BRCA2-what next? Multifactorial segregation analyses of three-generation, population-based Australian families affected by female breast cancer.
    Cui J; Antoniou AC; Dite GS; Southey MC; Venter DJ; Easton DF; Giles GG; McCredie MR; Hopper JL
    Am J Hum Genet; 2001 Feb; 68(2):420-31. PubMed ID: 11133358
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
    Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
    J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    McLaughlin JR; Risch HA; Lubinski J; Moller P; Ghadirian P; Lynch H; Karlan B; Fishman D; Rosen B; Neuhausen SL; Offit K; Kauff N; Domchek S; Tung N; Friedman E; Foulkes W; Sun P; Narod SA;
    Lancet Oncol; 2007 Jan; 8(1):26-34. PubMed ID: 17196508
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group.
    Narod SA; Brunet JS; Ghadirian P; Robson M; Heimdal K; Neuhausen SL; Stoppa-Lyonnet D; Lerman C; Pasini B; de los Rios P; Weber B; Lynch H;
    Lancet; 2000 Dec; 356(9245):1876-81. PubMed ID: 11130383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a case-control study.
    Evans DG; Brentnall A; Byers H; Harkness E; Stavrinos P; Howell A; ; Newman WG; Cuzick J
    J Med Genet; 2017 Feb; 54(2):111-113. PubMed ID: 27794048
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study.
    Narod SA; Sun P; Ghadirian P; Lynch H; Isaacs C; Garber J; Weber B; Karlan B; Fishman D; Rosen B; Tung N; Neuhausen SL
    Lancet; 2001 May; 357(9267):1467-70. PubMed ID: 11377596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A population study of mutations and LOH at breast cancer gene loci in tumours from sister pairs: two recurrent mutations seem to account for all BRCA1/BRCA2 linked breast cancer in Iceland.
    Arason A; Jonasdottir A; Barkardottir RB; Bergthorsson JT; Teare MD; Easton DF; Egilsson V
    J Med Genet; 1998 Jun; 35(6):446-9. PubMed ID: 9643283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers.
    Huo Z; Giger ML; Olopade OI; Wolverton DE; Weber BL; Metz CE; Zhong W; Cummings SA
    Radiology; 2002 Nov; 225(2):519-26. PubMed ID: 12409590
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
    Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
    Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.
    Lancet; 1997 May; 349(9064):1505-10. PubMed ID: 9167459
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
    Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
    Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Survey of BRCA1, BRCA2, and PALB2 mutations in women with breast cancer in Trinidad and Tobago.
    Donenberg T; Ahmed H; Royer R; Zhang S; Narod SA; George S; Akbari MR; Ali J; Hurley J
    Breast Cancer Res Treat; 2016 Aug; 159(1):131-8. PubMed ID: 27469594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.